large_pharma

DAIICHI SANKYO

Sponsor view across the ADC target screen, including linked targets and source-linked trial evidence.

ADC target activity

Tracked targets

Target	Trial count	Evidence
HER2 / ERBB2	1	Source
DLL3	1	Source

Linked trials

NCTADC001: Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast Cancer (RECRUITING)
NCTADC004: Ifinatamab Deruxtecan in Small Cell Lung Cancer (RECRUITING)